Search Results

Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto

Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer His research team has pioneered the study of G proteins and G protein coupled receptors (GPCRs) in human Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr.

Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically

- present: Researcher associate, Netherlands Brain Bank" Cheng-Chih Hsiao on the web LinkedIn ReseachGate Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. " About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology, Institute of Diabetes and Cancer Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes

Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer Trejo’s research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation , and cancer and is an important drug target. San Diego Trejo Lab Wikipedia LinkedIn Google Scholar Orcid Twitter UC San Diego School of Medicine Researchgate

unique academic journey—from early interests in medicine to his pivot toward pharmacology and GPCR research His research centers on the beta-2 adrenergic receptor and GPR65 , a proton-sensing receptor with promising implications in cancer biology. Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy My research has looked at the trafficking and signaling of adrenergic and proton-sensing receptors, with

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

GPCR Ecosystem and beyond About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic

was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic novel medicines for cancer treatment."

University of Utah School of Medicine in Salt Lake City, UT, and an investigator with the Huntsman Cancer Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development and in cancer. Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Guillaume Sandoz's group in 2019 as a postdoctoral research scientist at Université Côte d‘Azur, France Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto disorders and cancer at Paraza Pharma Inc. in Montreal. Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer (IRIC the development of innovative treatments for a range of diseases, including psychiatric disorders and cancer

This week's GPCR roll-up includes the latest insights, research discoveries, and advancements. Conformational Landscapes Rajan Lamichhane Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK G Protein-coupled Receptor Kinases and Arrestins - USA December 16 - 18, 2025 |Pharmacology 2025 - UK mediators of tumour-to-TME crosstalk Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer

Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Angers established his independent research program in the Department of Pharmaceutical Sciences at the He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams

UK, Wellcome Trust, and the Medical Research Council. She obtained her PhD in 2012 from the University of Oxford, where her research focused on the cellular Caroline moved to the University of Birmingham in 2018 to establish her research group investigating Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and working on the study of membrane trafficking processes in pancreatic beta cells before returning to the UK

GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the My experience in basic research at several universities worldwide and early R&D at Novo Nordisk A/S allowed Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer , and cancer and is an important drug target.

Caroline Formstone Abstract "Breast cancer is the most common form of cancer amongst women. Biochemistry and Molecular Biology, University of New Mexico" About Jianxiang Xue "I am a postdoctoral researcher Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA" About Bill Huang "Researcher I completed my Master’s thesis on ADGRL3, where I conducted research involving mammalian cell cultures Currently, my research focuses on the intracellular signaling of ADGRL3 from a single-molecule perspective

professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools She then joined the University of Santiago de Compostela as a postdoctoral researcher in Prof. Research , a leading innovator in fluorescent ligand technology, to bring high-performance chemical Custom Development Tailored fluorescent probes designed for unique research requirements. Ready to Advance your Drug Discovery Research?

Following a post-doctoral period at Bristol Myers Squibb in Princeton USA, Andrew returned to the UK Funded through three consecutive Wellcome Trust Senior Research Fellowships Andrew established a reputation Now at the University of Glasgow, his primary research interests are focused on the rational design of In this Andrew runs a research laboratory of around 15 staff supported by basic research grants investigating research.

Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer During her postdoctoral training at New York University School of Medicine, her research focused on cellular

Her research focuses on understanding the fundamental cell biological mechanisms regulating GPCR activity Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes UK, Wellcome Trust, and the Medical Research Council. Aylin Hanyaloglu on the web LinkedIn Researchgate Twitter Imperial College London Elsevier Loop Dr.

His research experience includes phylogenetics and cancer epigenetics.

of Medicine, where he studies BAI1's role in the brain and the radiobiology of treatments for brain cancer Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Laboratory, The Francis Crick Institute, UK 2Proteomics Science Technology Platform, The Francis Crick Institute, UK" About Simeon R. Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila

The research group led by Dr. located in the Centro de Biología Molecular “Severo Ochoa” (UAM/CSIC) and belongs also to the Health Research (GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer